Company Profile
Viking Therapeutics Stock Price, News & Analysis
- Ticker:
- VKTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
33.30 USD (-0.63%)
Close
Last updated: August 6, 2026
3.4B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, VKTX closed down 0.63% at $33.30. No new same-company headline was identified in the current news window.
Company overview
Obesity-Focused Metabolic Biotech
Viking Therapeutics is a clinical-stage biotechnology company advancing therapies for obesity and metabolic disease. Its pipeline is led by VK2735 and supported by additional obesity, liver/metabolic, and rare disease programs.
Lead Franchise: VK2735
VK2735 is a wholly owned dual GLP-1/GIP receptor agonist in development for obesity and related metabolic disorders. Viking is developing both subcutaneous and oral formulations, giving the program a differentiated profile across induction, long-term maintenance, and patient preference.
Phase 3 and Oral Development
The subcutaneous formulation is being evaluated in the Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials, both of which are fully enrolled. Viking is also preparing to start Phase 3 trials of oral VK2735 in the fourth quarter of 2026, positioning the oral program as a potential first oral dual GLP-1/GIP agonist.
Broader Metabolic Pipeline
Viking is expanding the obesity franchise with VK3019, an investigational dual amylin and calcitonin receptor agonist now in Phase 1. The company also lists VK2809, an oral thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for X-linked adrenoleukodystrophy.
Future catalysts
VK2735 maintenance dosing data expected in the third quarter of 2026.
Phase 3 oral VK2735 trial initiation expected in the fourth quarter of 2026.
VK3019 Phase 1 single-ascending-dose study readouts when the trial reports.
Recent news
- 01
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Source: Viking Therapeutics
- 02
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
Source: Viking Therapeutics
- 03
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Source: Viking Therapeutics
- 04
- 05
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
Source: Viking Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Viking Therapeutics (VKTX)?
Viking Therapeutics (VKTX) most recently closed at 33.30 USD, a -0.63% move versus the previous session.
What is the market cap of Viking Therapeutics (VKTX)?
Viking Therapeutics currently has a market capitalization of 3.4B USD on BioPharmSignal.
What does Viking Therapeutics do?
Obesity-Focused Metabolic Biotech Viking Therapeutics is a clinical-stage biotechnology company advancing therapies for obesity and metabolic disease. Its pipeline is led by VK2735 and supported by additional obesity, liver/metabolic, and rare disease programs. Lead Franchise: VK2735 VK2735 is a wholly owned dual GLP-1/GIP receptor agonist in development...
On which exchange is VKTX stock listed?
Viking Therapeutics (VKTX) is associated with NASDAQ, United States, Biopharma.
What is GLP-1?
Lead Franchise: VK2735 VK2735 is a wholly owned dual GLP-1/GIP receptor agonist in development for obesity and related metabolic disorders.
Which conditions is Viking Therapeutics targeting with GLP-1?
Viking Therapeutics is associated with rare disease, metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Viking Therapeutics describe recent progress with GLP-1?
VK2735 maintenance dosing data expected in the third quarter of 2026. Phase 3 oral VK2735 trial initiation expected in the fourth quarter of 2026. VK3019 Phase 1 single-ascending-dose study readouts when the trial reports.
What is VANQUISH-1?
Phase 3 and Oral Development The subcutaneous formulation is being evaluated in the Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials, both of which are fully enrolled.